Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 30.
doi: 10.1245/s10434-025-17740-9. Online ahead of print.

Clinical Application of Multimodal Sentinel Lymph Node-Mapping Method for Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy: A Final Analysis

Eun-Gyeong Lee  1 , Dong-Eun Lee  2 , So-Youn Jung  1 , Jai Hong Han  1 , Seok-Ki Kim  3 , Heejung Chae  4   5 , Sung Hoon Sim  4 , Keun Seok Lee  4 , Seeyoun Lee  6
Affiliations

Clinical Application of Multimodal Sentinel Lymph Node-Mapping Method for Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy: A Final Analysis

Eun-Gyeong Lee et al. Ann Surg Oncol. .

Abstract

Background: Neoadjuvant chemotherapy (NAC) leads to a nodal pathologic complete response (pCR) in approximately 70% of breast cancer patients, especially in human epidermal growth factor receptor 2 (HER2)-positive and triple-negative subtypes. However, sentinel lymph node (SLN)-mapping after NAC remains challenging due to lower identification and higher false-negative rates compared with early-stage breast cancer. This study aimed to evaluate the efficacy of a multimodal SLN-mapping approach after NAC.

Methods: This prospective, single-center, randomized controlled trial enrolled 270 patients with breast cancer receiving NAC between May 2021 and July 2024 and randomized them (1:1:1) to arm A (radioisotope [RI] + indocyanine green fluorescence [ICG-F]), arm B (RI + vital dye [indigo carmine]), and arm C (ICG-F + vital dye). The primary outcome of SLN-identification rate and the secondary outcome of SLN-operation time were analyzed.

Result: Interim results showed SLN-identification rates of 95% in arm A, 92% in arm B, and 79% in arm C, with a significant difference between arms A and C (0.1597; p = 0.0055). The final analysis comparing only arms A and B showed SLN-identification rates of 92.6% (100/108) and 90.6% (96/106), respectively (p = 0.2967), with a significantly shorter mean time to first SLN detection in arm B than in arm A (7 vs. 8 min; p = 0.0046). The intra-arm detection rates differed significantly: arm A (RI, 96.0%; ICG-F, 92.0%; p = 0.232) versus arm B (RI, 97.9%; vital dye, 72.9%; p < 0.0001).

Conclusion: Multimodal SLN-mapping demonstrated high post-NAC identification rates without significant intra-arm differences in the SLN-identification rates, whereas SLN-detection rates differed by the method for each arm. For patients with breast cancer, RI + ICG-F SLN-mapping is an effective dual-method post-NAC approach.

Keywords: Breast cancer; Indocyanine green fluorescence; Neoadjuvant chemotherapy; Sentinel node biopsy.

PubMed Disclaimer

References

    1. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220:391–8. https://doi.org/10.1097/00000658-199409000-00015 . (discussion 398–401). - DOI - PubMed - PMC
    1. Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol. 1993;2:335–9. https://doi.org/10.1016/0960-7404(93)90064-6 . (discussion 340). - DOI - PubMed
    1. Hennessy BT, et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol. 2005;23:9304–11. https://doi.org/10.1200/jco.2005.02.5023 . - DOI - PubMed
    1. Kuerer HM, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17:460–9. https://doi.org/10.1200/jco.1999.17.2.460 . - DOI - PubMed
    1. Boughey JC, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310:1455–61. https://doi.org/10.1001/jama.2013.278932 . - DOI - PubMed - PMC

LinkOut - more resources